You can buy or sell FENC and other stocks, options, ETFs, and crypto commission-free!
Fennec Pharmaceuticals Inc. Common Stock, also called Fennec Pharmaceuticals, is a biopharmaceutical company, which engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. Read More The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
Durham, North Carolina
52 Week High
52 Week Low
Stock Price, News, & Analysis for Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is...
-$0.14 per share
-$0.15 per share